Endevica Bio (formerly TCI Peptide Therapeutics) started in 2009, focusing on peptides that affect the melanocortin system, which mammals use to regulate food intake and energy homeostasis. The company’s core focus is on a drug candidate known as TCMCB07, a potential treatment for cachexia in cancer patients. Cachexia, a wasting disorder that can result in…